Detecting Neuroendocrine Prostate Cancer Through Tissue-Informed Cell-Free DNA Methylation Analysis
Abstract
Neuroendocrine prostate cancer (NEPC) is a resistance phenotype that emerges in men with metastatic castration-resistant prostate adenocarcinoma (CR-PRAD) and has important clinical implications, but is challenging to detect in practice. Herein, we report a novel tissue–informed epigenetic approach to noninvasively detect NEPC.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 01, 2022
- Source ID
- 10.1158/1078-0432.ccr-21-3762
Entities
People
- Eva Corey
- Harrison K. Tsai
- Heather M. McClure
- Himisha Beltran
- Jacob E Berchuck
- Ji-Heui Seo
- John A. Steinharter
- Joonghoon Auh
- Kaitlin M. Kelleher
- Keegan Korthauer
- Mark M. Pomerantz
- Mary-ellen Taplin
- Matthew L Freedman
- Michael Sigouros
- Michelle S Hirsch
- Monica He
- Olivier Elemento
- Pier Vitale Nuzzo
- Soumya Zacharia
- Sylvan C. Baca
- Sándor Spisák
- Toni K Choueiri
- Vincenza Conteduca
Organizations
- Dana–Farber Cancer Institute
- Harvard Medical School
- National Cancer Institute
- United States Department of Defense
- University of British Columbia
- University of Foggia
- University of Washington
- Weill Cornell Medicine